Impact of EU label changes and regulatory communication on SARS-CoV-2 adenovirus vector vaccines

For more information on this project, please contact the EU PE&PV research network at eupepv@uu.nl.

Project information

  • EU PE&PV research network
  • EUPAS44970
  • Specific Contract 02 implementing Framework service contract EMA/2018/23/PE

Full title

Impact of EU label changes and regulatory communication on SARS-CoV-2 adenovirus vector vaccines in context of thrombosis with thrombocytopenia syndrome (TTS): risk awareness and adherence (RiskAwareTTS) 

Principal investigator

Dr. Teresa Meneses Leonardo Alves, RIVM - project coordinator
Prof. Dr. Olaf Klungel, Utrecht University, EU PE&PV lead

Participating organisations

  • Utrecht University, The Netherlands - consortium lead
  • RIVM, The Netherlands - coordinator
  • University of Copenhagen, Denmark 
  • University of Porto, Portugal 
  • Democritus University of Thrace, Greece 
  • Rīga Stradiņš University, Latvia 
  • University of Ljubljana, Faculty of Pharmacy, Slovenia 

Status

Completed (2023)

Deliverables

Peer-reviewed scientific publications

Public's perspective on COVID-19 adenovirus vector vaccines after thrombosis with thrombocytopenia syndrome (TTS) reports and associated regulatory actions - A cross-sectional study in six EU member states. Buhl C, Jacobsen R, Almarsdóttir AB, Abtahi S, Andersen A, Deligianni E, Dermiki-Gkana F, Kontogiorgis C, Oikonomou C, Kursite M, Poplavska E, Hegger I, van der Goot M, Sousa Ferreira PB, Ribeiro-Vaz I, Silva AM, Kos M, Lipovec NČ, van Vliet E, Alves TL. Vaccine. 2024 Jan 4:S0264-410X(23)01511-6. doi: 10.1016/j.vaccine.2023.12.065. Epub ahead of print. PMID: 38182460.